Biopharma Dealmaking in 2022: Trends & Forecasts
2021 was a busy year in biopharma dealmaking. There were billion-dollar deals, a flood of funding, increased early-stage partnering, and new therapeutic areas and platforms coming online. Now, armed with record amounts of cash and funding, 2022 is poised to be another remarkable year for life science companies in general and partnering specifically.
Join Chris Dokomajilar, CEO at DealForma, and Echo Zhang, Product Strategy Director at Inova, as they discuss:
- Partnering and dealmaking trends in 2021
- What lies ahead in 2022
Please complete the form below
All fields marked with a * are required.
personal data by Inova as detailed in the Privacy Statement.
Download the Biopharma Dealmaking in 2022 eBook:
- 2021 Deal Numbers: Number of Deals Across Therapeutics and Platforms.
- Asset Types and Progress: Large Cap Biopharma Dealmaking Heading into 2022.
- Healthcare and Life Sciences Venture: Venture Totals into Healthcare and Life Sciences by Subsector.